Immunovia published prospectus in connection with the change of listing venue to Nasdaq Stockholm

LUND, Sweden ― Earlier today, Nasdaq Stockholm’s listing committee approved Immunovia AB’s (publ) (“Immunovia” or the “Company”) application for admission to trading of the Company’s shares on the regulated marked Nasdaq Stockholm. The prospectus that has been prepared in connection with the change of listing venue has today been approved and registered by the Swedish Financial Supervisory Authority and published on Immunovia’s website, www.immunovia.com.

First day of trading on Nasdaq Stockholm is 3 April 2018, and the last day of trading on Nasdaq First North is 29 March 2018. The share will continue to be traded under the same ticker (IMMNOV) and ISIN code (SE0006091997). The share will be subject to trading on Nasdaq Stockholm’s Mid Cap segment (and not Small Cap as previously stated). Shareholders of Immunovia do not need to take any actions in connection with the change of listing venue.

Within a few days, the prospectus will also be available on the Swedish Financial Supervisory Authority’s website, www.fi.se.

Adviser

Baker McKenzie is Immunovia’s legal adviser in connection with the listing on Nasdaq Stockholm.

For more information, please contact:

Mats Grahn

CEO, Immunovia

Tel.: +46-70-5320230

Email: mats.grahn@immunovia.com

About Immunovia 
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)

Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.

###

About Us

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com) Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.

Subscribe

Documents & Links